-
AstraZeneca buys Spirogen for up to $440 million
LONDON — AstraZeneca has acquired a British developer of biotech drugs for treating cancer, AstraZeneca said Tuesday.
The company said its MedImmune subsidiary had acquired privately held Spirogen and also entered into a collaboration with ADC Therapeutics to develop two of ADC's antibody-drug conjugate programs, currently in pre-clinical development. MedImmune will make an equity investment in ADC, which has an existing licensing agreement with Spirogen.
-
Diplomat receives ASHP accreditation for post-graduate residency program
FLINT, Mich. — The American Society of Health System Pharmacists has granted accreditation to a post-graduate program offered by specialty pharmacy Diplomat, the company said.
Diplomat, which recently shortened its name from Diplomat Specialty Pharmacy, received ASHP accreditation for its postgraduate year one, or PGY1 pharmacy residency program.